Liquidia wins FDA Fast Track for YUTREPIA in SSc—RP
Liquidia (LQDA) received FDA Fast Track for YUTREPIA inhalation powder in SSc—RP. The company is preparing a ~75-patient Phase 2a RE—WARM trial, enrolling Oct 2026 and targeting primary completion Feb 2027.